At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 589 enrolled
Drug / intervention
Troriluzole +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo- Controlled Trial of Adjunctive Troriluzole in Obsessive Compulsive Disorder
In Brief
A Phase 3 clinical trial evaluating Troriluzole and Placebo for Obsessive-Compulsive Disorder. Completed, enrolled 589 participants across 89 sites in 7 countries.
Detailed Summary
The purpose of this study was to evaluate the efficacy and safety of troriluzole as adjunctive therapy compared to placebo in participants with Obsessive Compulsive Disorder (OCD).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObsessive-Compulsive Disorder
CountriesCanada, China, Italy, Netherlands, Spain, United Kingdom, United States
Collaborators--
Timeline
Phase 3CompletedFinished
202120222023202420252026
First PostedJan 2021
Enrollment StartJan 2021
Primary CompletionApr 2025
TodayJul 2026
First PostedJan 5, 2021
Enrollment StartJan 29, 2021
Primary CompletionApr 29, 2025
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 5.5 years ago
Interventions
Troriluzoledrug
Capsules for oral administration.
Placebodrug
Drug- matching capsules for oral administration.